newsfilter
← Latest News
GlobeNewswire·

Immutep Quarterly Activities Report Q4 FY26

Media Release Pooled analysis of five efti trials (presented at ASCO 2026) reinforced efti's mechanism of action, tying immune activation to a 7.7-month median overall survival benefit in biological responders